Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$4.10 USD
-0.32 (-7.14%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.20 +0.11 (2.56%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Brokerage Reports
Puma Biotechnology, Inc. [PBYI]
Reports for Purchase
Showing records 41 - 60 ( 224 total )
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Nerlynx Net Product Sales Beat Our Estimate; Alisertib Data Expected in 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Nerlynx Additions to Updated NCCN Guidelines For the Treatment of Breast Cancer Patients With a HER2 Mutation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Nerlynx Sales Rise; Updated SUMMIT Trial Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Interim Results From Phase 2 SUMMIT Basket Trial of Nerlynx in EGFR Exon 18-Mutant NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WRIGHT J
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Just What the Doctor Ordered; Alisertib In-Licensed
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Nerlynx Sales Exceed Our Expectations, But We Are Reining in Our Estimates; Lowering PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Nerlynx (neratinib) Generic Receives Tentative Approval; 30-Month Stay Triggered
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E